Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease-Reference-Cited by-同舟云学术

Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease

Published:2022-01-05 Issue:1 Volume:5 Page:e2142078
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Bhattarai Mukul¹,Salih Mohsin¹,Regmi Manjari¹,Al-Akchar Mohammad¹,Deshpande Radhika²,Niaz Zurain²,Kulkarni Abhishek¹,Siddique Momin¹,Hegde Shruti¹

Affiliation:

1. Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield

2. Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2787632/bhattarai_2022_oi_211172_1640186079.15769.pdf

Reference25 articles.

1. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.;Sun;BMJ Open,2014

2. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.;Perkovic;N Engl J Med,2019

3. Sotagliflozin in patients with diabetes and chronic kidney disease.;Bhatt;N Engl J Med,2021

4. Canagliflozin and cardiovascular and renal events in type 2 diabetes.;Neal;N Engl J Med,2017

5. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.;Zinman;N Engl J Med,2015

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of canagliflozin combined with metformin therapy on reducing cardiovascular risk in type 2 diabetes patients;Diabetology & Metabolic Syndrome;2024-08-17

2. Profiling heart failure with preserved or mildly reduced ejection fraction by cluster analysis;European Heart Journal - Quality of Care and Clinical Outcomes;2024-08-08

3. Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial;Cardiovascular Diabetology;2024-07-11

4. Adjunctive therapy with an oral H₂S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction;British Journal of Pharmacology;2024-07-09

5. Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients;Future Cardiology;2024-07-04